A New Breed of Biotechs is Taking a Lead

by Andrii Buvailo 

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   2637    Comments 0

A Hong Kong-based artificial intelligence (AI)-driven drug discovery company Insilico Medicine has just announced the appointment of Dr. Michelle Chen as a Chief Business Officer (CBO) to oversee the company’s corporate strategies and business development activities. Dr. Chen is a lofty hire, having more than 20 years of experience in biopharma and such brands as WuXi Biologics, Roche, Merck, and BioMarin on her resume’s executive track record. 

Image credit: hakule, iStockPhoto.com

The news comes as a continuation of Insilico Medicine's hiring spree, including recent C-suite appointments of Nirav Jhaveri as Chief Financial Officer (CFO) and Dr. Robert Spiegel, the former Chief Medical Officer (CMO) of Schering Plough, as CMO to oversee the advancement of Insilico’s therapeutic pipeline. It also follows the company’s impressive growth trajectory, including a streak of collaboration milestone achievements, AI-software deployments, and a recent $255 million Series C financing led by Warburg Pincus in June. The financing was also participated by a group of prominent investors with expertise in biotechnology and artificial intelligence.

Insilico Medicine’s external partnerships have been piling up, including the company’s recent target discovery collaboration with Teva, a partnership with protein degradation pioneers Arvinas, and PAQ Therapeutics. Insilico’s growth in China is exceeding ambitious expectations with a substantial partnership struck at a rate of almost one every two weeks, according to the companies press release. 

The prominent growth dynamic is enabled by Insilico’s ability to deliver successful drug candidates out of its AI-driven system Pharma.AI in a remarkably “conveyor” fashion -- both for the internal pipeline and for the external partnerships. Pharma.AI includes three essential components: PandaOmics -- for multi-omics target discovery and deep biology analysis; Chemistry42 -- for machine learning de-novo design of novel drug-like molecules, and InClinico -- for predicting clinical trials success rates, and optimizing trial experiment design.

Continue reading

This content available exclusively for BPT Mebmers

Topics: Emerging Technologies    Industry Trends    Biotech Companies   

Share this:              

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *

SHARE